Company profile
Swedish Orphan Biovitrum AB (publ)
SOBI · Nasdaq Stockholm (Sobi is a Sweden-based specialty pharma (haematology, immunology, rare disease) publicly listed on Nasdaq Stockholm under SOBI; not found on our current company roster under this or the 'Sobi' short name. Sources: https://clinicaltrials.gov/study/NCT00452777 ; https://api.gleif.org/api/v1/lei-records/549300124Y3MQI87PT35 ; https://api.gleif.org/api/v1/lei-records/213800FUKFFW5J8E7N16 ; https://www.marketscreener.com/quote/stock/SWEDISH-ORPHAN-BIOVITRUM--6499130/ ; https://en.wikipedia.org/wiki/Swedish_Orphan_Biovitrum Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Swedish Orphan Biovitrum AB (publ) are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Pegcetacoplan(Empaveli) | Approved | Complement C3Small molecule | Chronic Kidney Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.